research Hair loss due to treatment of multiple sclerosis
Hair loss from multiple sclerosis treatments is usually temporary.
Search
for
Sort by
Research
780-810 / 1000+ results 
research Abstract 2469: Increased cathepsin B expression in cultured tuberous sclerosis skin tumor cells and patient tumor tissues
Skin tumor cells in patients with tuberous sclerosis have higher levels of a protein called cathepsin B.
research Tuberous sclerosis: Clinical findings in 57 patients
Most patients with Tuberous sclerosis had neurological or skin issues, and over half had psychiatric problems.
research Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
research Pain in Multiple Sclerosis: Understanding Pathophysiology, Diagnosis, and Management Through Clinical Vignettes
Effective pain management in multiple sclerosis requires individualized treatment strategies.
research Teriflunomide in multiple sclerosis: an update
Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
research Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice?
Hair thinning is a common but generally mild and reversible side effect of teriflunomide in multiple sclerosis patients.
research Experimental Production of Cutaneous Calcinosis and Sclerosis with Dihydrotachysterol (AT-10) 1
Giving dihydrotachysterol to mother rats caused skin hardening and bone issues in their babies through milk.
research Disease-Modifying Therapy in Multiple Sclerosis: Strategies For Optimizing Management
A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.
research Teriflunomide (Aubagio®) for the treatment of multiple sclerosis
Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
research Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response.
Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.
research The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis
New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
research Alopecia Universalis in a Multiple Sclerosis Patient After Switching From Rituximab to Ocrelizumab: A Case Report
Ocrelizumab may cause total body hair loss in some patients.
research Role of isoflavones in multiple sclerosis
Isoflavones from soy may help manage multiple sclerosis symptoms, but more research is needed.
research Exploring the Dermoscopic Patterns in Tuberous Sclerosis
Dermoscopy can help diagnose tuberous sclerosis by identifying unique skin patterns.
research BH25 Alopecia in a patient undergoing multiple treatments for multiple sclerosis: a rare presentation and case review
MS treatments can cause significant hair loss, affecting mental health.
research 3162 Alopecia universalis after alemtuzumab in multiple sclerosis - a nine year follow up and review of literature
Alopecia universalis from alemtuzumab in multiple sclerosis can be reversed with specific treatments.
research Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis
Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
research Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
research The Significance of NOTCH Pathway in the Development of Fibrosis in Systemic Sclerosis
Blocking the NOTCH pathway can prevent fibrosis in systemic sclerosis.
research Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
research Does Post-Void Residual Volume Predict Worsening Urological Symptoms in Patients with Multiple Sclerosis?
Post-void residual volume does not predict worsening urological symptoms in multiple sclerosis patients.
research A different approach to hair analysis: Application to multiple sclerosis
Manganese levels in hair may be linked to multiple sclerosis.
research Erosive pustular dermatosis of the scalp and multiple sclerosis: just a coincidence?
EPDS and MS might share an immune-related cause.
research The effect of changes in temperature on peripheral blood flow in systemic sclerosis
Warming hands improves blood flow in people with systemic sclerosis.
research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
research The emerging role of cellular senescence in amyotrophic lateral sclerosis
Cellular senescence may play a role in ALS, and anti-senescence therapies could be a promising treatment.
research Is Dutasteride a Therapeutic Alternative for Amyotrophic Lateral Sclerosis?
Dutasteride, usually used for prostate issues and hair loss, could potentially treat Amyotrophic Lateral Sclerosis (ALS) due to its neuroprotective, antioxidant, and anti-inflammatory properties, but more testing is needed.
research Delayed Onset of Alopecia Areata in a Patient on Ocrelizumab for Multiple Sclerosis: A Case Report
Ocrelizumab may cause delayed hair loss in some patients.
research Alemtuzumab-Induced Secondary Autoimmune Skin Disorders as Side Effects of Multiple Sclerosis Therapy: Problem That Can Be Influenced or Fate? A Narrative Overview of The Literature A Neuroprotective Role of Vitamin D?
Taking vitamin D might improve life for MS patients and reduce skin side effects from alemtuzumab treatment.